Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 Expression
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Azenosertib (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- 21 Oct 2024 Planned initiation date changed from 18 Oct 2024 to 7 Jul 2025.
- 21 Oct 2024 Status changed from not yet recruiting to recruiting.
- 19 Sep 2024 Planned End Date changed from 31 Mar 2026 to 8 Jul 2027.